1. Canada Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Plans
NexgenRx Inc.

NexgenRx Inc.

NEGXF
NexgenRx Inc.US flagOther OTC
0.27
USD
- -
- -
19.20MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.09
0.08
0.08
0.1
0.09
0.11
0.14
0.16
0.17
0.18
0.2
0.23
0.25
0.26
Basic EPS, GAAP
0.01
-0.01
- -
0.01
-0.01
-0.01
- -
0.03
0.06
- -
-0.01
0.01
0.01
0.03
Free Cash Flow per Basic Share
0.01
-0.01
- -
0.01
-0.01
-0.01
- -
0.02
0.03
0.01
0.01
0.01
0.07
0.06
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.01
0.01
0.01
0.02
0.02
Book Value per Share
-0.38
-0.39
-0.36
-0.34
-0.03
-0.03
-0.03
- -
0.05
0.04
0.02
0.02
0.02
0.04
Tangible Book Value per Share
- -
-0.01
- -
0.01
0.02
-0.05
-0.06
-0.03
0.02
0.03
0.02
0.03
0.05
0.07
Basic Weighted Avg Shares
56
56
57
59
60
68
70
70
70
70
71
71
71
72
Sales/Revenue/Turnover
5
4
5
6
6
7
10
11
12
13
14
16
18
18
Operating Margin (%)
14.56
-9.05
-6.99
8.98
-9.34
-7.78
0.98
19.55
18.57
2.25
-1.04
7.27
12.45
15.95
Depreciation Expense
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
1
1
Net Income, GAAP
1
- -
- -
1
-1
-1
- -
2
4
- -
- -
1
1
2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
116.66
- -
40.14
33.37
24.49
Profit Margin (%)
12.39
-11.33
-4.01
10.21
-11.04
-9.72
-2.18
19.16
33.93
-0.18
-2.4
3.73
7.19
10.83
Working Capital
- -
- -
- -
- -
1
-1
-3
-1
1
1
1
2
4
5
LT Debt
- -
- -
- -
- -
- -
1
1
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
1
2
2
2
6
10
9
8
8
8
9
Return on Invested Capital (%)
267.29
- -
- -
- -
- -
- -
- -
- -
- -
-0.49
- -
8.77
18.43
24.88
Return on Capital (%)
-3.08
- -
- -
- -
- -
- -
- -
- -
- -
-0.49
- -
16.75
35.55
44.65
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.68
-23.37
25.52
67.07
82.16

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
2
2
2
Shares Outstanding
71
71
71
Market Capitalization
20
28
27

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
34
32
37
Cash, Cash Equivalents & STI
3
5
5
Accounts Receivable, Net
1
1
1
Inventories
- -
- -
- -
Total Current Liabilities
31
29
32
Payables & Accruals
- -
2
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-59.76%
10.6%
-0.04%
Free Cash Flow
140.85%
99.94%
456.24%
Net Income, GAAP
-59.89%
239.2%
109.86%
Sales/Revenue/Turnover
14.78%
10.27%
8.84%
Total Cash Common Dividend
- -
144.45%
50.21%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4
4
4
4
16
2025
4
4
5
4
18
2026
5
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.01
2025
0.01
- -
0.01
- -
0.01
2026
0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
- -
- -
0.01
2025
- -
0.01
0.01
- -
0.02
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Ronald C. Loucks
Full Time Employees
20
Sector
Healthcare
Industry
Medical - Healthcare Plans
Address
185 The West Mall Toronto ON Canada M9C 5L5
IPO Date
Dec 18, 2017
Website
nexgenrx.com
Similar Companies
Humana Inc. (0J6Z.L)
Sipai Health Technology Co., Ltd. (0314.HK)
Cigna Corporation (CI)
Qualicorp Consultoria e Corretora de Seguros S.A. (QUAL3.SA)
Elevance Health Inc. (0HG8.L)
Caring Brands, Inc. (CBRA)
Business
NexgenRx Inc. (NEGXF) provides technology platforms as a software-as-a-service provider for administering, adjudicating, and paying drug, dental, extended health-care, and pension claims for group benefit plans in Canada; its core offerings include NexSys for claims adjudication of dental, prescription drug, and extended health claims; NexAdmin for flexible plan administration and self-administration; NexPension for multi-employer pension contribution management; and NexPSPAssist for patient support programs offered to pharmaceutical manufacturers. The company, founded in 2003 and headquartered at 191 The West Mall, Suite 905, Toronto, Ontario, Canada, primarily serves employers, unions, insurers, multi-employer trusts, and plan sponsors, processing over $1 billion in annual claim payments for 1 million lives covered. Recent developments feature strong revenue growth of $2.6 million in 2024, alongside strategic client acquisitions including a milestone partner onboarded in April 2025 that drove 167% year-over-year EBITDA increase to $627,631 in Q2 2025 through scalable SaaS expansion and enhanced implementation services.

Company News

APIChat

  • accessnewswire.com

    NexgenRx Announces Solid Q1 2026 Results with Continued Increasing Revenue, Net Income and EBITDA Growth

  • accessnewswire.com

    NexgenRx Announces Declaration of Divdend

  • accessnewswire.com

    NexgenRx Announces 2025 Year End Results with Continued Increasing Net Income, EBITDA And Revenue Growth

  • accessnewswire.com

    NexgenRx Announces Declaration of Divdends

  • accessnewswire.com

    NexgenRx Announces Declaration of Dividends

  • accessnewswire.com

    NexgenRx Announces Significant Third Quarter Revenue and EBITDA Growth

  • accessnewswire.com

    NexgenRx Announces Declaration of Dividend

  • accessnewswire.com

    NexgenRx Announces Second Quarter Results with Significant Revenue Growth and Positive EBITDA

  • accessnewswire.com

    NexgenRx Announces First Quarter Results With Solid Revenue Growth and Positive EBITDA

  • accessnewswire.com

    NexgenRx Announces Declaration of Divdend

  • accessnewswire.com

    NexgenRx Announces 2024 Year End Results with Continued Strong Revenue Growth and Increasing Positive EBITDA

  • accesswire.com

    NexgenRx Announces Third Quarter Results and Declaration of Divdend

  • accesswire.com

    NexgenRX Announces Director Re-Appointment

  • accesswire.com

    NexgenRx Announces New Director

  • accesswire.com

    NexgenRx Announces Second Quarter Results, With Over 19% Revenue Growth and Positive EBITDA

  • accesswire.com

    NexgenRx Announces Share Issuances Under Consulting Agreement

  • accesswire.com

    NexgenRx Announces Declaration of Dividend

  • accesswire.com

    NexgenRx Announces First Quarter Results, with 24% Revenue Growth and Record Earnings

  • accesswire.com

    NexgenRx Announces Annual Meeting Results

  • accesswire.com

    NexgenRx Announces 2023 Year End Results With Solid Revenue Growth, Continuing Positive EBITDA